Dentsply Sirona (XRAY)
(Delayed Data from NSDQ)
$26.71 USD
+0.02 (0.07%)
Updated Sep 18, 2024 04:00 PM ET
After-Market: $26.74 +0.03 (0.11%) 7:34 PM ET
4-Sell of 5 4
A Value B Growth C Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$26.71 USD
+0.02 (0.07%)
Updated Sep 18, 2024 04:00 PM ET
After-Market: $26.74 +0.03 (0.11%) 7:34 PM ET
4-Sell of 5 4
A Value B Growth C Momentum A VGM
Zacks News
Is a Beat Likely for DENTSPLY SIRONA (XRAY) in Q3 Earnings?
by Zacks Equity Research
DENTSPLY SIRONA's (XRAY) third-quarter 2023 results are likely to reflect a recovery in demand for consumable products, partially offset by lower sales in China due to volume-based procurement policy.
Cardinal Health (CAH) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Cardinal (CAH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Hologic (HOLX) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Strength in Breast Health and GYN Surgical businesses will likely drive Hologic's (HOLX) Q4 revenues.
McKesson (MCK) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
McKesson's (MCK) second-quarter fiscal 2024 results are likely to reflect the solid display by the U.S. Pharmaceutical and Specialty Solutions segment.
Merit Medical (MMSI) Beats Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Merit Medical (MMSI) delivered earnings and revenue surprises of 15.38% and 2.93%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?
Ecolab (ECL) to Report Q3 Earnings: What's in the Offing?
by Zacks Equity Research
Ecolab's (ECL) third-quarter results are likely to reflect continued segmental strength.
Revvity (RVTY) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Revvity's (RVTY) third-quarter results are likely to reflect weak performance at the Diagnostics segment, partially offset by strong demand for Life Sciences and Diagnostics franchise.
Dentsply International (XRAY) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Dentsply (XRAY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
What's in Store for Canopy Growth (CGC) in Q2 Earnings?
by Zacks Equity Research
In the second quarter of fiscal 2024, Canopy Growth (CGS) is expected to demonstrate an improved performance in the Canadian cannabis business.
DexCom (DXCM) to Report Q3 Earnings: Is a Beat in Store?
by Zacks Equity Research
DexCom's (DXCM) third-quarter 2023 results are likely to reflect rising volumes across all channels.
InMode (INMD) to Post Q3 Earnings: What's in the Cards?
by Zacks Equity Research
InMode (INMD) is likely to register growth in Q3, backed by strong consumable and service revenues and ongoing global expansion.
CVS Health (CVS) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
CVS Health (CVS) Q3 revenues will likely benefit from growth in specialty pharmacy and brand inflation and increased prescription and front store volume.
Will the Medicare Unit Aid Molina Healthcare's (MOH) Q3 Earnings?
by Zacks Equity Research
Molina Healthcare's (MOH) Q3 results are expected to benefit on growing premiums and an expanding customer base within its Medicaid and Medicare businesses, partly offset by increased medical costs.
Labcorp (LH) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Labcorp's (LH) third-quarter 2023 performance is likely to have witnessed strength in the Diagnostics Laboratories base business.
IDEXX Laboratories (IDXX) to Post Q3 Earnings: What's in Store?
by Zacks Equity Research
IDEXX Laboratories' (IDXX) third-quarter 2023 results are expected to reflect an impressive performance of the CAG segment.
What's in Store for Option Care Health (OPCH) in Q3 Earnings?
by Zacks Equity Research
Option Care Health's (OPCH) Q3 results are likely to be driven by sustained strong utilization.
Will Patient Volumes Aid Community Health's (CYH) Q3 Earnings?
by Zacks Equity Research
Community Health's (CYH) third-quarter results are likely to benefit from improved payer mix and growing surgery volumes, partly offset by a decline in patient days.
Elevance Health (ELV) Q3 Earnings Beat on Carelon Unit Strength
by Zacks Equity Research
Membership growth in the Medicare Advantage business and strong segmental performance aid Elevance Health's (ELV) Q3 results. An encouraging 2023 earnings guidance also bodes well for investors.
XRAY or COO: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
XRAY vs. COO: Which Stock Is the Better Value Option?
Reasons to Retain DENTSPLY SIRONA (XRAY) in Your Portfolio
by Zacks Equity Research
DENTSPLY SIRONA (XRAY) continues to gain traction from a robust product portfolio. However, macroeconomic factors like weakened global demand, rising costs and forex woes persist.
Reasons to Add The Cooper Companies (COO) to Your Portfolio
by Zacks Equity Research
The Cooper Companies (COO) continues to benefit from strength in its business segments. Its acquisitions are likely to drive the top line further.
DENTSPLY SIRONA (XRAY) Beats on Q2 Earnings, Ups '23 EPS View
by Zacks Equity Research
DENTSPLY SIRONA's (XRAY) Q2 revenues are driven by a rise in demand across key markets, especially in China. Improved pricing and restructuring initiatives boost earnings.
Is a Beat Likely for DENTSPLY SIRONA (XRAY) in Q2 Earnings?
by Zacks Equity Research
DENTSPLY SIRONA's (XRAY) second-quarter 2023 results are likely to reflect recovery in demand for consumable products, partially offset by lower sales in China due to volume-based procurement policy.
Charles River (CRL) to Report Q2 Earnings: What's in Store?
by Zacks Equity Research
Continued global demand for research models and associated services' strong DSA segment performance is likely to have driven Charles River's (CRL) Q2 revenues.
InMode (INMD) to Post Q2 Earnings: What's in the Cards?
by Zacks Equity Research
InMode (INMD) is expected to report strong Q2 consumable and service revenues, banking on strong performances of seven patented technologies across 10 product families.